The Pradaxa blood thinner has been the subject of concern for the past several years, focusing on the internal bleeding complications allegedly caused by the medication.

Pradaxa was approved by the FDA in 2010 to treat patients suffering from atrial fibrillation and who are at high risk for stroke.

Numerous patients allege the Pradaxa blood thinner had caused them to suffer uncontrollable bleeding injuries, many of which required emergency intervention.

Like other anticoagulants, the Pradaxa blood thinner works by inhibiting the body’s clotting mechanism and improves the overall circulation system.

However the body’s ability to recover from internal bleeding injuries is also inhibited, placing the patients at high risk for internal bleeding injuries.

Not long after its release, patients started submitting internal bleeding reports in alleged result of using the Pradaxa blood thinner.

By 2011, the FDA had received over 2,300 reports of “serious bleeding events” from patients prescribed Pradaxa.

Overview of Pradaxa Bleeding Concerns

For years after its release, there had been no bleeding antidote available in the case of these potentially fatal complications.

Recently, Boehringer Ingelheim developed Praxbind to remedy the situation. Similar to how vitamin K is used to stop internal bleeding in Warfarin patients, Praxbind can be implemented for patients suffering from Pradaxa bleeding complications.

Before the release of Praxbind, many complained that the Pradaxa blood thinner warning label lacked sufficient warnings against internal bleeding complications and failed to mention there was no available reversal agent.

Praxbind had been approved though the FDA’s accelerated program, after the drug had performed very well in numerous safety trials.

Until the release of Praxbind, Warfarin was the only anticoagulant with a readily available bleeding antidote.

When Pradaxa was released, it was the first medication to break into the anticoagulant market since Warfarin’s release in the 1960s. The Pradaxa blood thinner quickly overtook Warfarin in popularity, as it could be prescribed in a single dose.

However, while incredibly popular, there had been over 500 deaths linked to the Pradaxa blood thinner by 2012.

Critics complained the medication had not been properly evaluated before being released into the United States, resulting in numerous internal bleeding incidents.

The Pradaxa blood thinner had been approved due to tightly controlled testing measures, which produced favorable results and ultimately earned approval from the FDA.

Many patients affected by Pradaxa bleeding complications have filed legal action against Boehringer Ingelheim, for failing to warn them against uncontrollable bleeding complications.

Potential claimants who suffered injury from Pradaxa can contact a specialized lawyer, to determine eligibility for a Pradaxa lawsuit.